Crossmark Global Holdings Inc. Raises Stake in Humana Inc. $HUM

Crossmark Global Holdings Inc. boosted its position in Humana Inc. (NYSE:HUM) by 28.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 10,375 shares of the insurance provider’s stock after acquiring an additional 2,320 shares during the period. Crossmark Global Holdings Inc.’s holdings in Humana were worth $2,657,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Ethic Inc. raised its stake in Humana by 5.2% in the 4th quarter. Ethic Inc. now owns 10,073 shares of the insurance provider’s stock valued at $2,580,000 after acquiring an additional 498 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of Humana in the fourth quarter worth about $91,000. Generali Asset Management SPA SGR increased its position in shares of Humana by 1.0% in the fourth quarter. Generali Asset Management SPA SGR now owns 7,966 shares of the insurance provider’s stock worth $2,040,000 after purchasing an additional 77 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Humana by 19.1% in the fourth quarter. Sequoia Financial Advisors LLC now owns 6,084 shares of the insurance provider’s stock worth $1,558,000 after purchasing an additional 975 shares during the last quarter. Finally, Swedbank AB increased its position in shares of Humana by 6.2% in the fourth quarter. Swedbank AB now owns 111,803 shares of the insurance provider’s stock worth $28,636,000 after purchasing an additional 6,534 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Stock Down 0.3%

Shares of HUM opened at $274.11 on Tuesday. The firm has a market cap of $32.91 billion, a P/E ratio of 29.32, a P/E/G ratio of 2.54 and a beta of 0.68. The stock has a 50 day simple moving average of $195.89 and a two-hundred day simple moving average of $226.27. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $315.35.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.97 by $0.34. The business had revenue of $39.65 billion during the quarter, compared to analyst estimates of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.Humana’s revenue for the quarter was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. On average, analysts forecast that Humana Inc. will post 9.06 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $3.54 annualized dividend and a yield of 1.3%. Humana’s dividend payout ratio is currently 37.86%.

Insider Transactions at Humana

In other news, insider Sanjay K. Shetty bought 810 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was acquired at an average price of $185.21 per share, with a total value of $150,020.10. Following the completion of the purchase, the insider directly owned 11,657 shares in the company, valued at $2,158,992.97. This represents a 7.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently weighed in on HUM. Jefferies Financial Group upped their price objective on shares of Humana from $235.00 to $290.00 in a research report on Thursday, April 30th. UBS Group upped their price objective on shares of Humana from $195.00 to $262.00 and gave the stock a “neutral” rating in a research report on Thursday, April 30th. Guggenheim upped their price objective on shares of Humana from $252.00 to $269.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. The Goldman Sachs Group upped their price objective on shares of Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a research report on Thursday, April 30th. Finally, Morgan Stanley set a $146.00 price objective on shares of Humana in a research report on Thursday, February 12th. Seven analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and a consensus target price of $247.61.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.